[1]杨帆,李平,朱大龙.原发性甲状旁腺功能亢进症诊治中的焦点问题[J].国际内分泌代谢杂志,2021,41(06):553-556,561.[doi:10.3760/cma.j.cn121383-20210924-09072]
　Yang Fan,Li Ping,Zhu Dalong..Focal points in the diagnosis and treatment of primary hyperparathyroidism[J].International Journal of Endocrinology and Metabolism,2021,41(06):553-556,561.[doi:10.3760/cma.j.cn121383-20210924-09072]
点击复制

原发性甲状旁腺功能亢进症诊治中的焦点问题()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年06期
页码:
553-556,561
栏目:
专家论坛
出版日期:
2021-12-20

文章信息/Info

Title:
Focal points in the diagnosis and treatment of primary hyperparathyroidism
作者:
杨帆; 李平; 朱大龙
南京大学医学院附属鼓楼医院内分泌科,国家代谢性疾病临床医学研究中心分中心 210008
Author(s):
Yang Fan;  Li Ping;  Zhu Dalong.
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Branch of National Clinical Research Centre for Metabolic Diseases, Nanjing 210008, China
关键词:
原发性甲状旁腺功能亢进症;  异位甲状旁腺功能亢进症;  定位
Keywords:
Primary hyperparathyroidism;  Ectopic hyperparathyroidism;  Location
DOI:
10.3760/cma.j.cn121383-20210924-09072
摘要:
原发性甲状旁腺功能亢进症(PHPT)是由甲状旁腺病理性分泌过多甲状旁腺激素(PTH)所致的钙磷代谢紊乱性疾病。多数PHPT为散发性,少数的遗传性PHPT常常被临床忽略。随着体检的普及,无症状PHPT的发现率显著提高,但其治疗时机的选择仍存在争议。此外,对于异位PHPT的精确定位是手术治疗的关键。本文就PHPT诊治过程中的一些关键问题展开讨论,为临床提供借鉴。
Abstract:
Primary hyperparathyroidism(PHPT)is a disorder of calcium and phosphorus metabolism caused by excessive parathyroid hormone(PTH)secreted by parathyroid glands. Most PHPTs are sporadic, and a few hereditary PHPTs are often ignored in clinic. With the popularization of physical examination, the discovery rate of asymptomatic PHPT has increased significantly, but the choice of treatment time is still controversial. In addition, the accurate positioning of ectopic PHPT is the key to surgical treatment. This review discusses some key problems in the diagnosis and treatment of PHPT, so as to provide reference for clinical practice.

参考文献/References:

[1] Bilezikian JP,Bandeira L,Khan A,et al.Hyperparathyroidism[J].Lancet,2018,391(10116):168-178.DOI:10.1016/S0140-6736(17)31430-7.
[2] Walker MD,Silverberg SJ.Primary hyperparathyroidism[J].Nat Rev Endocrinol,2018,14(2):115-125.DOI:10.1038/nrendo.2017.104.
[3] Cusano NE,Cipriani C,Bilezikian JP.Management of normocalcemic primary hyperparathyroidism[J].Best Pract Res Clin Endocrinol Metab,2018,32(6):837-845.DOI:10.1016/j.beem.2018.09.009.
[4] Sun B,Guo B,Wu B,et al.Characteristics,management,and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016[J].Osteoporos Int,2018,29(3):635-642.DOI:10.1007/s00198-017-4322-7.
[5] Bilezikian JP,Brandi ML,Eastell R,et al.Guidelines for the management of asymptomatic primary hyperparathyroidism:summary statement from the Fourth International Workshop[J].J Clin Endocrinol Metab,2014,99(10):3561-3569.DOI:10.1210/jc.2014-1413.
[6] Rubin MR,Bilezikian JP,McMahon DJ,et al.The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years[J].J Clin Endocrinol Metab,2008,93(9):3462-3470.DOI:10.1210/jc.2007-1215.
[7] Vadhwana B,Currow C,Bowers D,et al.Impact on quality of life after parathyroidectomy for asymptomatic primary hyperparathyroidism[J].J Surg Res,2021,261:139-145.DOI:10.1016/j.jss.2020.12.023.
[8] Anagnostis P,Vaitsi K,Veneti S,et al.Efficacy of parathyroidectomy compared with active surveillance in patients with mild asymptomatic primary hyperparathyroidism:a systematic review and meta-analysis of randomized-controlled studies[J].J Endocrinol Invest,2021,44(6):1127-1137.DOI:10.1007/s40618-020-01447-7.
[9] Cetani F,Saponaro F,Borsari S,et al.Familial and hereditary forms of primary hyperparathyroidism[J].Front Horm Res,2019,51:40-51.DOI:10.1159/000491037.
[10] Balsalobre Salmeron M,Rodriguez Gonzalez JM,Ríos A,et al.Primary hyperparathyroidism associated with MEN 1:experience in 71 cases[J].Cir Esp(Engl Ed),2018,96(10):627-633.DOI:10.1016/j.ciresp.2018.06.014.
[11] Torresan F,Iacobone M.Clinical features,treatment,and surveillance of hyperparathyroidism-jaw tumor syndrome:an up-to-date and review of the literature[J].Int J Endocrinol,2019,2019:1761030.DOI:10.1155/2019/1761030.
[12] Marx SJ,Sinaii N.Neonatal severe hyperparathyroidism:novel insights from calcium,PTH,and the CASR gene[J].J Clin Endocrinol Metab,2020,105(4):1061-1078.DOI:10.1210/clinem/dgz233.
[13] Marx SJ.New concepts about familial isolated hyperparathyroidism[J].J Clin Endocrinol Metab,2019,104(9):4058-4066.DOI:10.1210/jc.2018-02789.
[14] Liu X,Sun L,Shao M,et al.Primary hyperparathyroidism due to ectopic parathyroid adenoma in an adolescent:a case report and review of the literature[J].Endocrine,2019,64(1):38-42.DOI:10.1007/s12020-019-01875-3.
[15] Andrade JS,Mangussi-Gomes JP,Rocha LA,et al.Localization of ectopic and supernumerary parathyroid glands in patients with secondary and tertiary hyperparathyroidism:surgical description and correlation with preoperative ultrasonography and Tc99m-Sestamibi scintigraphy[J].Braz J Otorhinolaryngol,2014,80(1):29-34.DOI:10.5935/1808-8694.20140008.
[16] Broome DT,Naples R,Bailey R,et al.Use of preoperative imaging in primary hyperparathyroidism[J].J Clin Endocrinol Metab,2021,106(1):e328-e337.DOI:10.1210/clinem/dgaa779.
[17] Walker MD,Silverberg SJ.Primary hyperparathyroidism[J].Nat Rev Endocrinol,2018,14(2):115-125.DOI:10.1038/nrendo.2017.104.
[18] Becker JL,Patel V,Johnson KJ,et al.4D-dynamic contrast-enhanced MRI for preoperative localization in patients with primary hyperparathyroidism[J].AJNR Am J Neuroradiol,2020,41(3):522-528.DOI:10.3174/ajnr.A6482.
[19] Cuderman A,Senica K,Rep S,et al.18F-fluorocholine PET/CT in primary hyperparathyroidism:superior diagnostic performance to conventional scintigraphic imaging for localization of hyperfunctioning parathyroid glands[J].J Nucl Med,2020,61(4):577-583.DOI:10.2967/jnumed.119.229914.
[20] Squires MH,Jarvis R,Shirley LA,et al.Intraoperative parathyroid autofluorescence detection in patients with primary hyperparathyroidism[J].Ann Surg Oncol,2019,26(4):1142-1148.DOI:10.1245/s10434-019-07161-w.
[21] Bhangu JS,Riss P.The role of intraoperative parathyroid hormone(IOPTH)determination for identification and surgical strategy of sporadic multiglandular disease in primary hyperparathyroidism(pHPT)[J].Best Pract Res Clin Endocrinol Metab,2019,33(5):101310.DOI:10.1016/j.beem.2019.101310.
[22] DeLong JC,Ward EP,Lwin TM,et al.Indocyanine green fluorescence-guided parathyroidectomy for primary hyperparathyroidism[J].Surgery,2018,163(2):388-392.DOI:10.1016/j.surg.2017.08.018.

相似文献/References:

[1]倪文婧 徐书杭 王建华 刘超.超声引导下热消融治疗原发性甲状旁腺功能亢进症的现状和展望[J].国际内分泌代谢杂志,2022,42(04):268.[doi:10.3760/cma.j.cn121383-20201223-12075]
　Ni Wenjing,Xu Shuhang,Wang Jianhua,et al.Current status and prospects of ultrasound-guided thermal ablation in the treatment of primary hyperparathyroidism[J].International Journal of Endocrinology and Metabolism,2022,42(06):268.[doi:10.3760/cma.j.cn121383-20201223-12075]
[2]张于芝,丁文波,武心萍,等.细针穿刺洗脱液甲状旁腺激素测定诊断原发性甲状旁腺功能亢进病灶的临床研究[J].国际内分泌代谢杂志,2024,44(01):14.[doi:10.3760/cma.j.cn121383-20221231-12054]
　Zhang Yuzhi,Ding Wenbo,Wu Xinping,et al.Clinical study on the diagnosis of primary hyperparathyroidism lesions with parathyroid hormone assay in fine needle aspiration washout[J].International Journal of Endocrinology and Metabolism,2024,44(06):14.[doi:10.3760/cma.j.cn121383-20221231-12054]

备注/Memo

备注/Memo:
通信作者:朱大龙, Email:zhudalong@nju.edu.cn
更新日期/Last Update: 2021-12-10